Google Cloud Managers Likely To Be Hit By Pay Cuts As Deal Growth Dries Up

As companies pull back on cloud projects and Alphabet Inc (NASDAQ:GOOG) (NASDAQ:GOOGL) Google’s deal growth slows, senior Google Cloud sales…
  • As companies pull back on cloud projects and Alphabet Inc (NASDAQ:GOOG) (NASDAQ:GOOGL) Google’s deal growth slows, senior Google Cloud sales leaders have told managers to expect changes in how the staff gets paid next year.
  • Executives at Google Cloud explored basing sales commissions on how much customers spend rather than the total contract value, the Information reports.
  • Also Read: Intel, Google Cloud Introduce Co-Developed Chip
  • Google, in recent years, signed billion-dollar, long-term deals with multinationals like Deutsche Bank AG (NYSE:DB) and Sabre Corp (NASDAQ:SABR), intensifying competition with Amazon.com Inc (NASDAQ:AMZNAmazon Web Services.
  • So far, Google has incentivized sales teams to nail those deals by basing a portion of their commissions on the value of the contracts, even if those customers did not spend the total amount on Google Cloud services.
  • Amazon dominated the cloud-infrastructure industry with a 39% share of the 2021 global market, ahead of Microsoft Corp (NASDAQ:MSFT) in the second position with a 21% share.
  • Tesla Inc (NASDAQ:TSLA) CEO Elon Musk has ordered Twitter Inc’s teams to find up to $1 billion in annual infrastructure cost savings. Cost cuts could also come from reduced spending on Google Cloud services.
  • Price Action: GOOG shares traded lower by 1.35% at $96.48 on the last check Monday.
  • Photo Via Company
Total
0
Shares
Related Posts
Read More

Immutep Announced Australian Patent Granted for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination With a PD-1 Pathway Inhibitor

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 2016205983) entitled "Combined Preparations for the Treatment of Cancer or Infection" by the Australian Patent Office.

IMMP